The past 30 years bear witness to a profound evolution in our ability to diagnose pediatric cancers. What were once common diagnostic dilemmas are now routinely categorized with the help of ancillary tests such as immunohistochemistry, fl uorescence in situ hybridization, and a myriad of molecular diagnostics tools. We are now moving into an unprecedented new realm wherein personalized medicin…